Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-01 |
{
"resourceType" : "Citation",
"id" : "179624",
"meta" : {
"versionId" : "8",
"lastUpdated" : "2024-07-18T17:58:30.068Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Citation 179624</b></p><a name=\"179624\"> </a><a name=\"hc179624\"> </a><a name=\"179624-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 8; Last updated: 2024-07-18 17:58:30+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-journal-article-citation.html\">JournalArticleCitation</a></p></div><p><b>url</b>: <a href=\"Citation-179624.html\">Citation 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</a></p><p><b>identifier</b>: FEvIR Object Identifier/179624, <code>https://pubmed.ncbi.nlm.nih.gov</code>/24598155, <a href=\"http://terminology.hl7.org/6.0.2/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.40</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-01 10:20:00+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use\">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}\">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title=\"Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}\">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>approvalDate</b>: 2015-01-02</p><p><b>lastReviewDate</b>: 2021-10-21</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type citation-source}\">Citation Source</span></p><p><b>classifier</b>: <span title=\"Codes:\">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}\">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}\">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type medline-medline}\">Medline Citation Status of Medline</span>, <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-epublish}\">PubMed PublicationStatus of epublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-received}\">PubMed Pubstatus of Received</span></p><p><b>period</b>: ?? --> 2013-12-27</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-accepted}\">PubMed Pubstatus of Accepted</span></p><p><b>period</b>: ?? --> 2014-02-25</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}\">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2014-03-07 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}\">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2014-03-07 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}\">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2015-01-03 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pmc-release}\">PubMed Pubstatus of PMC release</span></p><p><b>period</b>: ?? --> 2014-03-05</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/24598155, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC3974001, <code>https://doi.org</code>/10.1186/1756-8722-7-20, pii/1756-8722-7-20</p><h3>Titles</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/title-type primary}\">Primary title</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></td><td><div><p>Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</p>\n</div></td></tr></table><h3>Abstracts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p><strong>BACKGROUND:</strong> Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP.\n<strong>METHODS:</strong> Patients (n\u2009=\u200930) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS).\n<strong>RESULTS:</strong> Median baseline PSA was 25.8 ng/ml (2.1-293), and the predicted probability of 5-year bRFS was 10% (0-55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p\u2009<\u20090.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (-31.3-82.8; p\u2009<\u20090.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3-131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individualized.\n<strong>CONCLUSIONS:</strong> NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical value needs further investigation in randomized trials.</p>\n</div></td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771. doi: 10.1093/jnci/90.10.766.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9605647/\">https://pubmed.ncbi.nlm.nih.gov/9605647/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9605647</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9749478/\">https://pubmed.ncbi.nlm.nih.gov/9749478/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9749478</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010;106(1):6–22.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/20553475/\">https://pubmed.ncbi.nlm.nih.gov/20553475/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/20553475</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. doi: 10.1016/S0140-6736(02)09408-4.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/12126818/\">https://pubmed.ncbi.nlm.nih.gov/12126818/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/12126818</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG. PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. doi: 10.1016/S0140-6736(11)61095-7.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/22056152/\">https://pubmed.ncbi.nlm.nih.gov/22056152/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/22056152</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17. doi: 10.1016/j.ctrv.2008.08.002.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18926640/\">https://pubmed.ncbi.nlm.nih.gov/18926640/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18926640</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–280. doi: 10.1111/j.1464-410X.2007.06760.x.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/17355369/\">https://pubmed.ncbi.nlm.nih.gov/17355369/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/17355369</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi: 10.1056/NEJMoa041318.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15470214/\">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi: 10.1200/JCO.2007.12.4008.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18182665/\">https://pubmed.ncbi.nlm.nih.gov/18182665/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18182665</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18. doi: 10.1186/1756-8722-4-18.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/21513551/\">https://pubmed.ncbi.nlm.nih.gov/21513551/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/21513551</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35. doi: 10.1186/1756-8722-5-35.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/22747660/\">https://pubmed.ncbi.nlm.nih.gov/22747660/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/22747660</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142. doi: 10.1016/j.urology.2004.01.040.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15183967/\">https://pubmed.ncbi.nlm.nih.gov/15183967/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15183967</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240. doi: 10.1158/1078-0432.CCR-05-0299.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/16033841/\">https://pubmed.ncbi.nlm.nih.gov/16033841/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/16033841</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254. doi: 10.1002/cncr.22897.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/17674353/\">https://pubmed.ncbi.nlm.nih.gov/17674353/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/17674353</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–1252. doi: 10.1038/sj.bjc.6605320.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/19755998/\">https://pubmed.ncbi.nlm.nih.gov/19755998/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/19755998</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–570. doi: 10.1016/j.juro.2008.04.012.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18554663/\">https://pubmed.ncbi.nlm.nih.gov/18554663/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18554663</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327. doi: 10.1016/j.urology.2007.08.060.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18308112/\">https://pubmed.ncbi.nlm.nih.gov/18308112/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18308112</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1. doi: 10.1186/1477-7819-10-1.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/22214417/\">https://pubmed.ncbi.nlm.nih.gov/22214417/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/22214417</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529. doi: 10.1016/S0090-4295(98)00542-1.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10096378/\">https://pubmed.ncbi.nlm.nih.gov/10096378/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10096378</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–708.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/14713791/\">https://pubmed.ncbi.nlm.nih.gov/14713791/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/14713791</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29(6):608–613. doi: 10.1016/j.urolonc.2009.09.012.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/20022268/\">https://pubmed.ncbi.nlm.nih.gov/20022268/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/20022268</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–713. doi: 10.1159/000020366.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11111188/\">https://pubmed.ncbi.nlm.nih.gov/11111188/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11111188</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780. doi: 10.1016/S0090-4295(02)02519-0.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/12670564/\">https://pubmed.ncbi.nlm.nih.gov/12670564/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/12670564</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/14747042/\">https://pubmed.ncbi.nlm.nih.gov/14747042/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/14747042</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>D’Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998;51(2):287–292. doi: 10.1016/S0090-4295(97)00610-9.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/9495713/\">https://pubmed.ncbi.nlm.nih.gov/9495713/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/9495713</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>D’Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008;71(1):9–15. doi: 10.1016/j.ijrobp.2007.09.033.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/18037582/\">https://pubmed.ncbi.nlm.nih.gov/18037582/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/18037582</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791. doi: 10.1002/cncr.24092.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/19130458/\">https://pubmed.ncbi.nlm.nih.gov/19130458/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/19130458</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. doi: 10.1016/j.eururo.2011.01.025.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/21315502/\">https://pubmed.ncbi.nlm.nih.gov/21315502/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/21315502</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167(2 Pt 2):1197–1203.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/11905901/\">https://pubmed.ncbi.nlm.nih.gov/11905901/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/11905901</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin V, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467.</p>\n</div><h3>Documents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/10550143/\">https://pubmed.ncbi.nlm.nih.gov/10550143/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/10550143</p></blockquote><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/published-in-type D020492}\">Periodical</span></p><p><b>identifier</b>: Electronic ISSN Type/1756-8722, ISOAbbreviation/J Hematol Oncol, ISSN Linking/1756-8722, Medline Title Abbreviation/J Hematol Oncol, NLM Unique ID/101468937</p><p><b>title</b>: Journal of hematology & oncology</p><p><b>publisherLocation</b>: England</p></blockquote><p><b>citedMedium</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-medium internet}\">Internet</span></p><p><b>volume</b>: 7</p><p><b>articleDate</b>: 2014-03-05</p><p><b>publicationDateText</b>: 2014-Mar-05</p><p><b>language</b>: <span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></p><p><b>pageString</b>: 20</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-medium internet-without-issue}\">Internet without issue</span></p><p><b>articleDate</b>: 2014-03-05</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}\">Abstract</span></p><p><b>url</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/24598155/\">https://pubmed.ncbi.nlm.nih.gov/24598155/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/artifact-url-classifier doi-based}\">DOI Based</span></p><p><b>url</b>: <a href=\"https://doi.org/10.1186/1756-8722-7-20\">https://doi.org/10.1186/1756-8722-7-20</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}\">Publishing Model</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier Electronic}\">Electronic</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}\">Chemical</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000726}\">Androgen Antagonists</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D043823}\">Taxoids</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 15H5577CQD}, {https://meshb.nlm.nih.gov/ D000077143}\">Docetaxel</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href=\"#hc179624/meshHeading0\">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}\">Publication type</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D017427}\">Clinical Trial, Phase II</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016428}\">Journal Article</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}\">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}\">Citation subset</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}\">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor0\">Thalgott M</a></p><p><b>forenameInitials</b>: M</p><p><b>affiliation</b>: Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, Munich 81675, Germany. mark.thalgott@lrz.tum.de.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor1\">Horn T</a></p><p><b>forenameInitials</b>: T</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor2\">Heck MM</a></p><p><b>forenameInitials</b>: MM</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor3\">Maurer T</a></p><p><b>forenameInitials</b>: T</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor4\">Eiber M</a></p><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor5\">Retz M</a></p><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor6\">Autenrieth M</a></p><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor7\">Herkommer K</a></p><p><b>forenameInitials</b>: K</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor8\">Krause BJ</a></p><p><b>forenameInitials</b>: BJ</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor9\">Gschwend JE</a></p><p><b>forenameInitials</b>: JE</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor10\">Treiber U</a></p><p><b>forenameInitials</b>: U</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179624/contributor11\">Kübler HR</a></p><p><b>forenameInitials</b>: HR</p></blockquote></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor0</b></p><a name=\"179624/contributor0\"> </a><a name=\"hc179624/contributor0\"> </a><a name=\"179624/contributor0-en-US\"> </a><p><b>name</b>: Mark Thalgott </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor1</b></p><a name=\"179624/contributor1\"> </a><a name=\"hc179624/contributor1\"> </a><a name=\"179624/contributor1-en-US\"> </a><p><b>name</b>: Thomas Horn </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor2</b></p><a name=\"179624/contributor2\"> </a><a name=\"hc179624/contributor2\"> </a><a name=\"179624/contributor2-en-US\"> </a><p><b>name</b>: Matthias M Heck </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor3</b></p><a name=\"179624/contributor3\"> </a><a name=\"hc179624/contributor3\"> </a><a name=\"179624/contributor3-en-US\"> </a><p><b>name</b>: Tobias Maurer </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor4</b></p><a name=\"179624/contributor4\"> </a><a name=\"hc179624/contributor4\"> </a><a name=\"179624/contributor4-en-US\"> </a><p><b>name</b>: Matthias Eiber </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor5</b></p><a name=\"179624/contributor5\"> </a><a name=\"hc179624/contributor5\"> </a><a name=\"179624/contributor5-en-US\"> </a><p><b>name</b>: Margitta Retz </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor6</b></p><a name=\"179624/contributor6\"> </a><a name=\"hc179624/contributor6\"> </a><a name=\"179624/contributor6-en-US\"> </a><p><b>name</b>: Michael Autenrieth </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor7</b></p><a name=\"179624/contributor7\"> </a><a name=\"hc179624/contributor7\"> </a><a name=\"179624/contributor7-en-US\"> </a><p><b>name</b>: Kathleen Herkommer </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor8</b></p><a name=\"179624/contributor8\"> </a><a name=\"hc179624/contributor8\"> </a><a name=\"179624/contributor8-en-US\"> </a><p><b>name</b>: Bernd J Krause </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor9</b></p><a name=\"179624/contributor9\"> </a><a name=\"hc179624/contributor9\"> </a><a name=\"179624/contributor9-en-US\"> </a><p><b>name</b>: Jürgen E Gschwend </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor10</b></p><a name=\"179624/contributor10\"> </a><a name=\"hc179624/contributor10\"> </a><a name=\"179624/contributor10-en-US\"> </a><p><b>name</b>: Uwe Treiber </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor11</b></p><a name=\"179624/contributor11\"> </a><a name=\"hc179624/contributor11\"> </a><a name=\"179624/contributor11-en-US\"> </a><p><b>name</b>: Hubert R Kübler </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name=\"179624/meshHeading0\"> </a><a name=\"hc179624/meshHeading0\"> </a><a name=\"179624/meshHeading0-en-US\"> </a><p><b>artifact</b>: <a href=\"#hc179624\">Citation 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000368}\">Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000726}\">Androgen Antagonists</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D018450}\">Disease Progression</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000077143}\">Docetaxel</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D006801}\">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D008297}\">Male</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D008875}\">Middle Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D020360}\">Neoadjuvant Therapy</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D011471}\">Prostatic Neoplasms</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000188}\">drug therapy</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000601}\">surgery</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016019}\">Survival Analysis</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D043823}\">Taxoids</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000009}\">adverse effects</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}\">No</span></td></tr></table></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016896}\">Treatment Outcome</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote></blockquote></div>"
},
"contained" : [
{
"resourceType" : "Practitioner",
"id" : "contributor0",
"name" : [
{
"family" : "Thalgott",
"given" : [
"Mark"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor1",
"name" : [
{
"family" : "Horn",
"given" : [
"Thomas"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor2",
"name" : [
{
"family" : "Heck",
"given" : [
"Matthias M"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor3",
"name" : [
{
"family" : "Maurer",
"given" : [
"Tobias"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor4",
"name" : [
{
"family" : "Eiber",
"given" : [
"Matthias"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor5",
"name" : [
{
"family" : "Retz",
"given" : [
"Margitta"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor6",
"name" : [
{
"family" : "Autenrieth",
"given" : [
"Michael"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor7",
"name" : [
{
"family" : "Herkommer",
"given" : [
"Kathleen"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor8",
"name" : [
{
"family" : "Krause",
"given" : [
"Bernd J"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor9",
"name" : [
{
"family" : "Gschwend",
"given" : [
"Jürgen E"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor10",
"name" : [
{
"family" : "Treiber",
"given" : [
"Uwe"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor11",
"name" : [
{
"family" : "Kübler",
"given" : [
"Hubert R"
]
}
]
},
{
"resourceType" : "ArtifactAssessment",
"id" : "meshHeading0",
"artifactReference" : {
"reference" : "#",
"type" : "Citation"
},
"content" : [
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000368",
"display" : "Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D018450",
"display" : "Disease Progression",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000077143",
"display" : "Docetaxel",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D006801",
"display" : "Humans",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D008297",
"display" : "Male",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D008875",
"display" : "Middle Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D020360",
"display" : "Neoadjuvant Therapy",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D011471",
"display" : "Prostatic Neoplasms",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000188",
"display" : "drug therapy"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000601",
"display" : "surgery"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016019",
"display" : "Survival Analysis",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D043823",
"display" : "Taxoids",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000009",
"display" : "adverse effects"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016896",
"display" : "Treatment Outcome",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
}
]
}
],
"url" : "https://fevir.net/resources/Citation/179624",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179624",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "24598155"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.15.40"
}
],
"version" : "2.0.0-ballot",
"title" : "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.",
"status" : "active",
"date" : "2024-11-01T10:20:00+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext" : [
{
"code" : {
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "fevir-platform-use",
"display" : "FEvIR Platform Use"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "medline-base",
"display" : "Medline Base",
"userSelected" : false
}
]
}
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate" : "2015-01-02",
"lastReviewDate" : "2021-10-21",
"author" : [
{
"name" : "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "citation-source",
"display" : "Citation Source"
}
]
},
"classifier" : [
{
"text" : "MEDLINE"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "medline-owner",
"display" : "MEDLINE Citation Owner"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code" : "NLM",
"display" : "National Library of Medicine, Index Section",
"userSelected" : false
}
]
}
]
}
],
"currentState" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "medline-medline",
"display" : "Medline Citation Status of Medline"
}
]
},
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-publication-status-epublish",
"display" : "PubMed PublicationStatus of epublish"
}
]
}
],
"statusDate" : [
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-received",
"display" : "PubMed Pubstatus of Received"
}
]
},
"period" : {
"end" : "2013-12-27"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-accepted",
"display" : "PubMed Pubstatus of Accepted"
}
]
},
"period" : {
"end" : "2014-02-25"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-entrez",
"display" : "PubMed Pubstatus of Entrez"
}
]
},
"period" : {
"end" : "2014-03-07T06:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pubmed",
"display" : "PubMed Pubstatus of Pubmed"
}
]
},
"period" : {
"end" : "2014-03-07T06:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-medline",
"display" : "PubMed Pubstatus of Medline"
}
]
},
"period" : {
"end" : "2015-01-03T06:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pmc-release",
"display" : "PubMed Pubstatus of PMC release"
}
]
},
"period" : {
"end" : "2014-03-05"
}
}
],
"citedArtifact" : {
"identifier" : [
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "24598155"
},
{
"system" : "https://www.ncbi.nlm.nih.gov/pmc/",
"value" : "PMC3974001"
},
{
"system" : "https://doi.org",
"value" : "10.1186/1756-8722-7-20"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "pii"
},
"value" : "1756-8722-7-20"
}
],
"title" : [
{
"type" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/title-type",
"code" : "primary",
"display" : "Primary title"
}
]
}
],
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
},
"text" : "Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."
}
],
"abstract" : [
{
"text" : "**BACKGROUND:** Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP.\n**METHODS:** Patients (n\u2009=\u200930) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS).\n**RESULTS:** Median baseline PSA was 25.8 ng/ml (2.1-293), and the predicted probability of 5-year bRFS was 10% (0-55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p\u2009<\u20090.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (-31.3-82.8; p\u2009<\u20090.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3-131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individualized.\n**CONCLUSIONS:** NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical value needs further investigation in randomized trials."
}
],
"relatesTo" : [
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771. doi: 10.1093/jnci/90.10.766.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9605647/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9605647",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9749478/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9749478",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010;106(1):6–22.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/20553475/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "20553475",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. doi: 10.1016/S0140-6736(02)09408-4.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/12126818/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "12126818",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG. PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. doi: 10.1016/S0140-6736(11)61095-7.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/22056152/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "22056152",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17. doi: 10.1016/j.ctrv.2008.08.002.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18926640/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18926640",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–280. doi: 10.1111/j.1464-410X.2007.06760.x.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/17355369/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "17355369",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi: 10.1056/NEJMoa041318.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/15470214/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15470214",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi: 10.1200/JCO.2007.12.4008.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18182665/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18182665",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18. doi: 10.1186/1756-8722-4-18.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/21513551/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "21513551",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35. doi: 10.1186/1756-8722-5-35.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/22747660/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "22747660",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142. doi: 10.1016/j.urology.2004.01.040.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/15183967/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15183967",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240. doi: 10.1158/1078-0432.CCR-05-0299.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/16033841/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "16033841",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254. doi: 10.1002/cncr.22897.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/17674353/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "17674353",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–1252. doi: 10.1038/sj.bjc.6605320.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/19755998/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19755998",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–570. doi: 10.1016/j.juro.2008.04.012.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18554663/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18554663",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327. doi: 10.1016/j.urology.2007.08.060.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18308112/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18308112",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1. doi: 10.1186/1477-7819-10-1.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/22214417/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "22214417",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529. doi: 10.1016/S0090-4295(98)00542-1.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10096378/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10096378",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–708.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/14713791/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "14713791",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29(6):608–613. doi: 10.1016/j.urolonc.2009.09.012.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/20022268/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "20022268",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–713. doi: 10.1159/000020366.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/11111188/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11111188",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780. doi: 10.1016/S0090-4295(02)02519-0.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/12670564/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "12670564",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/14747042/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "14747042",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "D’Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998;51(2):287–292. doi: 10.1016/S0090-4295(97)00610-9.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/9495713/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9495713",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "D’Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008;71(1):9–15. doi: 10.1016/j.ijrobp.2007.09.033.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/18037582/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18037582",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791. doi: 10.1002/cncr.24092.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/19130458/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19130458",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. doi: 10.1016/j.eururo.2011.01.025.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/21315502/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "21315502",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167(2 Pt 2):1197–1203.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/11905901/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11905901",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin V, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467.",
"document" : {
"url" : "https://pubmed.ncbi.nlm.nih.gov/10550143/"
},
"resourceReference" : {
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10550143",
"assigner" : {
"display" : "NLM"
}
}
}
}
],
"publicationForm" : [
{
"publishedIn" : {
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/published-in-type",
"code" : "D020492",
"display" : "Periodical"
}
]
},
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code" : "Electronic",
"display" : "Electronic"
}
],
"text" : "Electronic ISSN Type"
},
"system" : "https://portal.issn.org",
"value" : "1756-8722"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISOAbbreviation"
},
"system" : "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value" : "J Hematol Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISSN Linking"
},
"system" : "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value" : "1756-8722"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "Medline Title Abbreviation"
},
"system" : "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value" : "J Hematol Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "NLM Unique ID"
},
"system" : "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value" : "101468937"
}
],
"title" : "Journal of hematology & oncology",
"publisherLocation" : "England"
},
"citedMedium" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-medium",
"code" : "internet",
"display" : "Internet"
}
]
},
"volume" : "7",
"articleDate" : "2014-03-05",
"publicationDateText" : "2014-Mar-05",
"language" : [
{
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
}
],
"pageString" : "20"
},
{
"citedMedium" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-medium",
"code" : "internet-without-issue",
"display" : "Internet without issue"
}
]
},
"articleDate" : "2014-03-05"
}
],
"webLocation" : [
{
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/artifact-url-classifier",
"code" : "abstract",
"display" : "Abstract"
}
]
}
],
"url" : "https://pubmed.ncbi.nlm.nih.gov/24598155/"
},
{
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/artifact-url-classifier",
"code" : "doi-based",
"display" : "DOI Based"
}
]
}
],
"url" : "https://doi.org/10.1186/1756-8722-7-20"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publishing-model",
"display" : "Publishing Model",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "Electronic",
"display" : "Electronic",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "chemical",
"display" : "Chemical",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D043823",
"display" : "Taxoids",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "15H5577CQD",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000077143",
"display" : "Docetaxel",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
]
},
"artifactAssessment" : [
{
"reference" : "#meshHeading0",
"type" : "ArtifactAssessment"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publication-type",
"display" : "Publication type"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D017427",
"display" : "Clinical Trial, Phase II",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "knowledge-artifact-type",
"display" : "Knowledge Artifact Type",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
}
],
"artifactAssessment" : [
{
"display" : "Classifier added by Computable Publishing LLC"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "citation-subset",
"display" : "Citation subset",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code" : "IM",
"display" : "IM",
"userSelected" : false
}
]
}
]
}
],
"contributorship" : {
"complete" : true,
"entry" : [
{
"contributor" : {
"reference" : "#contributor0",
"type" : "Practitioner",
"display" : "Thalgott M"
},
"forenameInitials" : "M",
"affiliation" : [
{
"display" : "Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, Munich 81675, Germany. mark.thalgott@lrz.tum.de."
}
]
},
{
"contributor" : {
"reference" : "#contributor1",
"type" : "Practitioner",
"display" : "Horn T"
},
"forenameInitials" : "T"
},
{
"contributor" : {
"reference" : "#contributor2",
"type" : "Practitioner",
"display" : "Heck MM"
},
"forenameInitials" : "MM"
},
{
"contributor" : {
"reference" : "#contributor3",
"type" : "Practitioner",
"display" : "Maurer T"
},
"forenameInitials" : "T"
},
{
"contributor" : {
"reference" : "#contributor4",
"type" : "Practitioner",
"display" : "Eiber M"
},
"forenameInitials" : "M"
},
{
"contributor" : {
"reference" : "#contributor5",
"type" : "Practitioner",
"display" : "Retz M"
},
"forenameInitials" : "M"
},
{
"contributor" : {
"reference" : "#contributor6",
"type" : "Practitioner",
"display" : "Autenrieth M"
},
"forenameInitials" : "M"
},
{
"contributor" : {
"reference" : "#contributor7",
"type" : "Practitioner",
"display" : "Herkommer K"
},
"forenameInitials" : "K"
},
{
"contributor" : {
"reference" : "#contributor8",
"type" : "Practitioner",
"display" : "Krause BJ"
},
"forenameInitials" : "BJ"
},
{
"contributor" : {
"reference" : "#contributor9",
"type" : "Practitioner",
"display" : "Gschwend JE"
},
"forenameInitials" : "JE"
},
{
"contributor" : {
"reference" : "#contributor10",
"type" : "Practitioner",
"display" : "Treiber U"
},
"forenameInitials" : "U"
},
{
"contributor" : {
"reference" : "#contributor11",
"type" : "Practitioner",
"display" : "Kübler HR"
},
"forenameInitials" : "HR"
}
]
}
}
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-01
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change